Catalog No.: PC-45068Not For Human Use, Lab Use Only.
A novel, potent, and selective inhibitor of Late sodium current (late INa) for treatment of long QT-3 syndrome (LQT-3), hypertrophic cardiomyopathy (HCM), and ventricular tachycardia–ventricular fibrillation (VT–VF).
Eleclazine (GS6615) hydrochloride is a potent, and selective inhibitor of Late sodium current (late INa) for treatment of long QT-3 syndrome (LQT-3), hypertrophic cardiomyopathy (HCM), and ventricular tachycardia–ventricular fibrillation (VT–VF).
Eleclazine (GS6615) is 42 times more potent than Ranolazine in reducing ischemic burden in vivo (EC50=190 nM).
